A 23-year-old experienced recurring catatonia episodes triggered by cannabis use

A young man with substance use history developed recurrent catatonia after cannabis use, requiring ongoing lorazepam above 2 mg daily to prevent relapse.

Moshfeghinia, Reza et al.·Frontiers in psychiatry·2024·Preliminary EvidenceCase Report
RTHC-05572Case ReportPreliminary Evidence2024RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
Case Report
Evidence
Preliminary Evidence
Sample
Not reported

What This Study Found

A 23-year-old male developed mutism, social isolation, and fixed gaze after cannabis use. Recurrent catatonic episodes without hallucinations were effectively treated with ECT and lorazepam, but symptoms returned when lorazepam dropped below 2 mg/day. The systematic literature review confirms cannabis-induced catatonia as a rare but documented phenomenon.

Key Numbers

23-year-old male. Recurrent episodes. Required lorazepam above 2 mg/day. ECT and lorazepam effective for acute episodes. 10% of psychiatric admissions involve catatonia overall.

How They Did This

Case report of recurrent cannabis-induced catatonia with systematic literature review.

Why This Research Matters

Cannabis-induced catatonia is rare but may be underdiagnosed because clinicians do not typically associate cannabis with this presentation.

The Bigger Picture

As cannabis potency increases, rare but serious psychiatric reactions may become more common, challenging the perception of cannabis as having only mild psychiatric effects.

What This Study Doesn't Tell Us

Single case report. Cannot establish definitive causation. Patient had prior substance use disorder. Systematic review likely found very few cases.

Questions This Raises

  • ?What factors predispose certain individuals to cannabis-induced catatonia?
  • ?Should catatonia screening be considered in psychiatric presentations following heavy cannabis use?

Trust & Context

Key Stat:
catatonic episodes triggered by cannabis use, requiring ongoing lorazepam above 2 mg/day
Evidence Grade:
Single case report with literature review. Useful for clinical awareness but cannot establish incidence.
Study Age:
2024 publication.
Original Title:
Recurrent cannabis-induced catatonia: a case report and comprehensive systematic literature review.
Published In:
Frontiers in psychiatry, 15, 1332310 (2024)
Database ID:
RTHC-05572

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / Observational
Case Report / Animal StudyOne case or non-human subjects
This study

Describes what happened to one person or a small group.

What do these levels mean? →

Frequently Asked Questions

Can cannabis cause catatonia?

This case documents recurrent catatonia triggered by cannabis. While rare, the association is documented. The mechanism likely involves disruption of dopamine and GABA neurotransmitter systems.

What is catatonia?

A neuropsychiatric syndrome involving motor, speech, and behavioral abnormalities. It affects about 10% of psychiatric admissions and can be life-threatening if untreated.

Read More on RethinkTHC

Cite This Study

RTHC-05572·https://rethinkthc.com/research/RTHC-05572

APA

Moshfeghinia, Reza; Hosseinzadeh, Mehrnaz; Mostafavi, Sara; Jabbarinejad, Roxana; Malekpour, Mahdi; Chohedri, Elnaz; Ahmadi, Jamshid. (2024). Recurrent cannabis-induced catatonia: a case report and comprehensive systematic literature review.. Frontiers in psychiatry, 15, 1332310. https://doi.org/10.3389/fpsyt.2024.1332310

MLA

Moshfeghinia, Reza, et al. "Recurrent cannabis-induced catatonia: a case report and comprehensive systematic literature review.." Frontiers in psychiatry, 2024. https://doi.org/10.3389/fpsyt.2024.1332310

RethinkTHC

RethinkTHC Research Database. "Recurrent cannabis-induced catatonia: a case report and comp..." RTHC-05572. Retrieved from https://rethinkthc.com/research/moshfeghinia-2024-recurrent-cannabisinduced-catatonia-a

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.